This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
A STEP toward the eventual control of hepatitis A has been taken with the licensure in February of the first vaccine against the disease. The Food and Drug Administration's (FDA) approval made the United States the 41st country in which the vaccine is available.
The inactivated vaccine, manufactured by SmithKline Beecham Biologicals, Philadelphia, Pa, is being marketed under the name Havrix. It will cost $43 per dose for adults and $15 per dose for those younger than 18 years. A second vaccine against hepatitis A, made by Merck Sharp & Dohme Research Laboratories, West Point, Pa, is also under active investigation.
Recommendations for use of the licensed vaccine are being prepared by the Hepatitis Branch of the Centers for Disease Control and Prevention (CDC), Atlanta, Ga, for the Advisory Committee on Immunization Practices. A draft was reviewed by the committee 2 weeks before the vaccine was licensed at its regular
Marwick C. Hepatitis A Vaccine Set for 2-Year-Olds to Adults. JAMA. 1995;273(12):906-907. doi:10.1001/jama.1995.03520360018006